Skip to main content

Table 1

From: Nivolumab dose selection: challenges, opportunities and lessons learned for cancer immunotherapy

  MEL (N=107) NSCLC (N=129) RCC (N-34)
Dose (mg/kg) ORR % (n/N) PFS 24 wks, % ORR % (n/N) PFS 24 wks, % ORR % (n/N) PFS 24 wks, %
0.1 35 (6/17) 41 - - - -
0.3 28 (5/18) 35 - - - -
1 31 (11/35) 51 3 (1/33) 26 28 (5/18) 50
3 41 (7/17) 55 24 (9/37) 40 - -
10 20 (4/20) 35 20 (12/59) 33 31 (5/16) 67